Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 555

1.

Platelet glycoprotein IIb/IIIa inhibition in acute coronary syndromes. Gradient of benefit related to the revascularization strategy.

Roffi M, Chew DP, Mukherjee D, Bhatt DL, White JA, Moliterno DJ, Heeschen C, Hamm CW, Robbins MA, Kleiman NS, Théroux P, White HD, Topol EJ.

Eur Heart J. 2002 Sep;23(18):1441-8.

PMID:
12208224
[PubMed - indexed for MEDLINE]
2.

Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: a meta-analysis of all major randomised clinical trials.

Boersma E, Harrington RA, Moliterno DJ, White H, Théroux P, Van de Werf F, de Torbal A, Armstrong PW, Wallentin LC, Wilcox RG, Simes J, Califf RM, Topol EJ, Simoons ML.

Lancet. 2002 Jan 19;359(9302):189-98. Erratum in: Lancet 2002 Jun 15;359(9323):2120.

PMID:
11812552
[PubMed - indexed for MEDLINE]
3.

Outcomes of patients with acute coronary syndromes who are treated with bivalirudin during percutaneous coronary intervention: an analysis from the Randomized Evaluation in PCI Linking Angiomax to Reduced Clinical Events (REPLACE-2) trial.

Rajagopal V, Lincoff AM, Cohen DJ, Gurm HS, Hu T, Desmet WJ, Kleiman NS, Bittl JA, Feit F, Topol EJ.

Am Heart J. 2006 Jul;152(1):149-54.

PMID:
16824845
[PubMed - indexed for MEDLINE]
4.

Recent antiplatelet drug trials in the acute coronary syndromes. Clinical interpretation of PRISM, PRISM-PLUS, PARAGON A and PURSUIT.

Alexander JH, Harrington RA.

Drugs. 1998 Dec;56(6):965-76. Review.

PMID:
9878986
[PubMed - indexed for MEDLINE]
5.

Bivalirudin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a subgroup analysis from the Acute Catheterization and Urgent Intervention Triage strategy (ACUITY) trial.

Stone GW, White HD, Ohman EM, Bertrand ME, Lincoff AM, McLaurin BT, Cox DA, Pocock SJ, Ware JH, Feit F, Colombo A, Manoukian SV, Lansky AJ, Mehran R, Moses JW; Acute Catheterization and Urgent Intervention Triage strategy (ACUITY) trial investigators.

Lancet. 2007 Mar 17;369(9565):907-19.

PMID:
17368152
[PubMed - indexed for MEDLINE]
6.

Benefit of an early invasive management strategy in women with acute coronary syndromes.

Glaser R, Herrmann HC, Murphy SA, Demopoulos LA, DiBattiste PM, Cannon CP, Braunwald E.

JAMA. 2002 Dec 25;288(24):3124-9.

PMID:
12495392
[PubMed - indexed for MEDLINE]
7.

Routine upstream initiation vs deferred selective use of glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: the ACUITY Timing trial.

Stone GW, Bertrand ME, Moses JW, Ohman EM, Lincoff AM, Ware JH, Pocock SJ, McLaurin BT, Cox DA, Jafar MZ, Chandna H, Hartmann F, Leisch F, Strasser RH, Desaga M, Stuckey TD, Zelman RB, Lieber IH, Cohen DJ, Mehran R, White HD; ACUITY Investigators.

JAMA. 2007 Feb 14;297(6):591-602.

PMID:
17299194
[PubMed - indexed for MEDLINE]
8.

Platelet glycoprotein IIb/IIIa inhibitors reduce mortality in diabetic patients with non-ST-segment-elevation acute coronary syndromes.

Roffi M, Chew DP, Mukherjee D, Bhatt DL, White JA, Heeschen C, Hamm CW, Moliterno DJ, Califf RM, White HD, Kleiman NS, Théroux P, Topol EJ.

Circulation. 2001 Dec 4;104(23):2767-71.

PMID:
11733392
[PubMed - indexed for MEDLINE]
Free Article
9.

Acute Catheterization and Urgent Intervention Triage strategY (ACUITY) trial: study design and rationale.

Stone GW, Bertrand M, Colombo A, Dangas G, Farkouh ME, Feit F, Lansky AJ, Lincoff AM, Mehran R, Moses JW, Ohman M, White HD.

Am Heart J. 2004 Nov;148(5):764-75.

PMID:
15523305
[PubMed - indexed for MEDLINE]
11.

Attenuation of rebound ischemia after discontinuation of heparin therapy by glycoprotein IIb/IIIa inhibition with eptifibatide in patients with acute coronary syndromes: observations from the platelet IIb/IIIa in unstable angina: receptor suppression using integrilin therapy (PURSUIT) trial.

Lauer MA, Houghtaling PL, Peterson JG, Granger CB, Bhatt DL, Sapp SK, Simoons ML, Harrington RA, Topol EJ, Lincoff AM; Platelet IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy (PURSUIT) Trial Investigators.

Circulation. 2001 Dec 4;104(23):2772-7.

PMID:
11733393
[PubMed - indexed for MEDLINE]
Free Article
12.

Promise of combined low-molecular-weight heparin and platelet glycoprotein IIb/IIIa inhibition: results from Platelet IIb/IIIa Antagonist for the Reduction of Acute coronary syndrome events in a Global Organization Network B (PARAGON B).

Mukherjee D, Mahaffey KW, Moliterno DJ, Harrington RA, Yadav JS, Pieper KS, Gallup D, Dyke C, Roe MT, Berdan L, Lauer MS, Mänttäri M, White HD, Califf RM, Topol EJ.

Am Heart J. 2002 Dec;144(6):995-1002.

PMID:
12486423
[PubMed - indexed for MEDLINE]
13.

Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban.

Cannon CP, Weintraub WS, Demopoulos LA, Vicari R, Frey MJ, Lakkis N, Neumann FJ, Robertson DH, DeLucca PT, DiBattiste PM, Gibson CM, Braunwald E; TACTICS (Treat Angina with Aggrastat and Determine Cost of Therapy with an Invasive or Conservative Strategy)--Thrombolysis in Myocardial Infarction 18 Investigators.

N Engl J Med. 2001 Jun 21;344(25):1879-87.

PMID:
11419424
[PubMed - indexed for MEDLINE]
Free Article
14.

[The clinical use of the GPIIb/IIIa inhibitors eptifibatide and tirofiban in the treatment of acute coronary syndromes of the "non-ST elevation" type].

Galli M, Maggioni AP, Vassanelli C, Tavazzi L.

Ital Heart J Suppl. 2000 Feb;1(2):202-11. Review. Italian.

PMID:
10731377
[PubMed - indexed for MEDLINE]
15.

Platelet glycoprotein IIb/IIIa receptor antagonists in cardiovascular disease.

Vorchheimer DA, Badimon JJ, Fuster V.

JAMA. 1999 Apr 21;281(15):1407-14. Review.

PMID:
10217057
[PubMed - indexed for MEDLINE]
17.

Safety and preliminary efficacy of one month glycoprotein IIb/IIIa inhibition with lefradafiban in patients with acute coronary syndromes without ST-elevation; a phase II study.

Akkerhuis KM, Neuhaus KL, Wilcox RG, Vahanian A, Boland JL, Hoffmann J, Baardman T, Nehmiz G, Roth U, Klootwijk AP, Deckers JW, Simoons ML; Fibrinogen Receptor Occupancy Study (FROST) Investigators.

Eur Heart J. 2000 Dec;21(24):2042-55.

PMID:
11102255
[PubMed - indexed for MEDLINE]
Free Article
18.

Platelet inhibitors in non-ST-segment elevation acute coronary syndromes and percutaneous coronary intervention: glycoprotein IIb/IIIa inhibitors, clopidogrel, or both?

Silva MA, Donovan JL, Gandhi PJ, Volturo GA.

Vasc Health Risk Manag. 2006;2(1):39-48. Review.

PMID:
17319468
[PubMed - indexed for MEDLINE]
Free PMC Article
19.

Early vs late administration of glycoprotein IIb/IIIa inhibitors in primary percutaneous coronary intervention of acute ST-segment elevation myocardial infarction: a meta-analysis.

Montalescot G, Borentain M, Payot L, Collet JP, Thomas D.

JAMA. 2004 Jul 21;292(3):362-6.

PMID:
15265852
[PubMed - indexed for MEDLINE]
20.

[GPIIB/IIIA blockade after high-risk angioplasty: new perspectives].

Smiri Z, Lahidheb D, Hajlaoui N, Barakett N, Rahal N, Azzouzi F, Fehri W, Mhenni H, Haouala H.

Tunis Med. 2003;81 Suppl 8:617-24. Review. French.

PMID:
14608749
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk